520 results on '"Fischereder, Michael"'
Search Results
2. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
3. Alternate‐day dosing of caplacizumab for immune‐mediated thrombotic thrombocytopenic purpura
4. Pathologische Urinbefunde - it's a MUST
5. Polyomavirus exerts detrimental effects on renal function in patients after lung transplantation
6. #2247 Influence of the diagnosis of atopic dermatitis in childhood on the course of kidney function in young adulthood: a single-center study
7. #1303 Hyperkalaemia-related RAASi reduction and estimated number needed to treat to avoid a first hospitalisation by maintaining RAASi
8. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
9. Nierentransplantation (NTX)
10. Chronische Nierenerkrankung
11. Autoren
12. The use of extended-release tacrolimus twice a day might be beneficial for selected kidney transplant recipients: a case report.
13. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy
14. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
15. Sapovirus – An emerging pathogen in renal transplant recipients?
16. Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial
17. Hyperkalzämie: Häufig steckt eine Tumorerkrankung dahinter: Onkologische Zufallsbefunde
18. Urin-Streifentest
19. Patients' and physicians' awareness of clinical symptoms and disease severity in tuberous sclerosis complex.
20. Symptoms and Occurrence of Hepatitis E in Solid-Organ Recipients: A Single-Center Experience of the Last Five Years: PUB292
21. Behandlung des sekundären Hyperparathyreoidismus bei Dialysepatienten und Transplantationserfolg
22. Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation
23. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
24. Unerwarteter Kreatininanstieg: Was steckt dahinter?
25. Corrigendum: Disqualification of donor and recipient candidates from the living kidney donation program: Experience of a single-center in Germany
26. Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial
27. Drug-induced CYP-Induction as Therapy for Tacrolimus Intoxication
28. Predisposing Diseases
29. Nierenschutz für Ihre Diabetiker
30. Disqualification of Donor and Recipient Candidates From the Living Kidney Donation Program: Experience of a Single-Center in Germany
31. Sirolimus in renal transplant recipients with malignancies in Germany
32. Diminished Short- and Long-Term Antibody Response after SARS-CoV-2 Vaccination in Hemodialysis Patients
33. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura
34. Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection
35. MO914: Development of Antibody Response to SARS-COV-2 Vaccines in Haemodialysis Patients
36. Diminished Short- and Long-Term Antibody Response after SARS-CoV-2 Vaccination in Hemodialysis Patients
37. Donor Toll-Like Receptor 4 Contributes to Ischemia and Reperfusion Injury following Human Kidney Transplantation
38. Immunsuppression und COVID-19
39. Drug-induced CYP-induction as therapy for tacrolimus intoxication
40. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
41. SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy
42. Reader Response: Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults
43. Humoral immunity to SARS-CoV-2 vaccination in haemodialysis patients
44. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
45. Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis
46. Wenn möglich: organerhaltend operieren: Behandlungsoptionen beim Nierenzellkarzinom
47. Thrombotic microangiopathy following aortic surgery with hypothermic circulatory arrest: a single-centre experience of an underestimated cause of acute renal failure
48. Antibody response to mRNA SARS-CoV-2 vaccines in haemodialysis patients
49. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
50. UREMIC TOXICITY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.